Crossmark

Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients

Crossref DOI link: https://doi.org/10.1186/s12954-019-0278-6

Published Online: 2019-01-28

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lucas, Philippe https://orcid.org/0000-0003-1948-3842
Baron, Eric P.

Jikomes, Nick
License Information

Text and Data Mining valid from 2019-01-28
More Information

Article History

Received: 7 December 2018

Accepted: 10 January 2019

First Online: 28 January 2019

Ethics approval and consent to participate

: This survey was ethics reviewed and approved by Advarra (formerly Institutional Review Board Services; reference # Pro00018492), and the University of Victoria subsequently approved a post-survey sub-analysis of the substitution data (reference # 17-188). A password-protected link to an online survey available in French and English was sent out to 16,675 Tilray patients in January 2017. Clicking on the link in the email invitation took patients to the IRB approved Informed Consent Form (ICF), and consent was gathered electronically.

: Not applicable.

: This research was supported by Tilray, a federally authorized Canadian medical cannabis production and research company. PL is Global Vice-President, Patient Research and Access for Tilray (), and he designed the survey. Formal analysis was conducted by EB, who has no conflict to disclose. Preliminary data analysis was conducted by NJ, Senior Science Advisor, Data & Analytics, at Leafly, an online cannabis website.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below